RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals plc) is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. We are currently commercializing Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
Events and Presentations
More information is coming soon.